Richard A. Heyman
CIK 1584759 · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DEL MAR, CA 92014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ORIC | Director | 241,772 | $8.97 | $2.17M | -$610.9K | 21 | 2026-10-02 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 149,218 | $14.59 | $2.18M | -$1.09M | 25 | 2026-02-19 |
| PMVP | Director | 975 | $1.19 | $1.2K | -$126.9K | 8 | 2025-06-09 |
| RayzeBio, Inc. (RYZB) Delisted | Director | 0 | $62.49 | $0 | $0 | 1 | 2024-02-27 |
| Metacrine, Inc. (MTCR) Delisted | Director | — | $0.49 | — | $0 | 2 | 2022-09-06 |
| Gritstone bio, Inc. (GRTS) Delisted | Director | — | $0.03 | — | $0 | 4 | 2022-06-22 |
| KINETA, INC./DE (YMTX) Delisted | Director | 1,160 | $13.23 | $15.3K | $0 | 3 | 2021-06-04 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | $0 | 3 | 2015-08-27 |
| VivoSim Labs, INC. (ONVO) Delisted | Director | — | $2.04 | — | $0 | 3 | 2015-08-24 |
Recent Filings · Page 6 of 10
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-20 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,270 | -$22.1K | EDGAR |
| 2024-02-20 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-15 | ELVN | Notice (144) | −3,810 | -$56.6K | EDGAR |
| 2024-02-15 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-01 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,270 | -$20.8K | EDGAR |
| 2023-12-26 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −216 | -$2.8K | EDGAR |
| 2023-12-21 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −4,280 | -$55.7K | EDGAR |
| 2023-12-20 | ELVN | Notice (144) | −1,956 | -$24.7K | EDGAR |
| 2023-12-19 | ELVN | Notice (144) | −3,810 | -$44.6K | EDGAR |
| 2023-06-15 | ORIC | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.